NB

Norbert Bischofberger

North America, California, United States, San Mateo

Description

Norbert Bischofberger is the Co-Founder of Rezo Therapeutics. He previously worked at Gilead Sciences as a Chief Scientific Officer. Norber...

Investor Profile

Norbert Bischofberger has made 2 investments, with 0 in the past 12 months and 0% as lead.

Stage Focus

  • Series A (50%)
  • Seed (50%)

Country Focus

  • United States (100%)

Industry Focus

  • Biotechnology
  • Chemical
  • Therapeutics
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Norbert Bischofberger frequently co-invest with?

Omega Funds
Europe, Geneve, Switzerland, Geneva
Co-Investments: 2
Nextech Invest
Europe, Zurich, Switzerland, Zürich
Co-Investments: 1
Google Ventures
North America, California, United States, Mountain View
Co-Investments: 1
Vida Ventures
North America, Massachusetts, United States, Boston
Co-Investments: 2
Bellco Capital
North America, California, United States, Los Angeles
Co-Investments: 1
Polaris Partners
North America, Massachusetts, United States, Boston
Co-Investments: 1
Perceptive Advisors
North America, New York, United States, New York
Co-Investments: 1
Two River
North America, New York, United States, New York
Co-Investments: 1
Invus
North America, New York, United States, New York
Co-Investments: 1

Which angels does Norbert Bischofberger often collaborate with?

AB
North America, California, United States, Los Angeles
Shared Deals: 1
Shared Deals: 1

What are some of recent deals done by Norbert Bischofberger?

Kronos Bio

San Mateo, California, United States

Kronos Bio focuses on the research and development of first-in-class therapies that modulate historically recalcitrant cancer.

BiotechnologyChemicalTherapeutics
Series AJul 18, 2019
Amount Raised: $105,000,000
Kronos Bio

San Mateo, California, United States

Kronos Bio focuses on the research and development of first-in-class therapies that modulate historically recalcitrant cancer.

BiotechnologyChemicalTherapeutics
SeedJun 5, 2018
Amount Raised: $18,000,000